

REMARKS

The above amendment added no new matter and is merely made to more accurately describe and claim the invention, and to claim benefit of priority.

It is respectfully submitted that the application is now in condition for allowance, which allowance is respectfully requested.

Respectfully submitted,

Kohn & Associates




Amy E. Binaldo
Reg. No. 45,791
30500 Northwestern Hwy.
Suite 410
Farmington Hills, MI 48334
(810) 539-5050

Dated: November 27, 2001

CERTIFICATE OF MAILING

Express Mail Label No. EV013719440US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 27, 2001.



Angel Webb

VERSION SHOWING CHANGES

6. (Amended) A method for the diagnosis of one of central nervous system (CNS) stress and disruption of the blood-brain-barrier in a mammal, comprising obtaining a sample from said mammal, contacting said sample with an antibody of [any one of] claim[s] 1 [to 5], removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

7. (Amended) A method for the diagnosis of one central nervous system (CNS) stress and disruption of the blood-brain-barrier in a mammal, comprising contacting a sample of said mammal with an antibody of [any one of] claim[s] 1 [to 5], removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

8. (Amended) The method of [any one of] claim[s] 6 [or 7], wherein the CNS stress is caused by one of physical, chemical and psychological insult.

11. (Amended) A method for the diagnosis of Alzheimer's disease in a subject, comprising obtaining a sample from said subject, contacting said sample with an antibody of [any one of] claim[s] 1 [to 5], removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

12. (Amended) A method for the diagnosis of Alzheimer's disease in a subject, comprising contacting a sample of said mammal with an antibody of [any one of] claim[s] 1 [to 5], removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

13. (Amended) A method according to [any one of] claim[s] 6 [to 10], wherein the sample is one of serum and cerebrospinal fluid sample.

14. (Amended) A method according to [any one of] claim[s] 11 [to 12], wherein the sample is one of serum and cerebrospinal fluid sample.

15. (Amended) Use of the antibodies of claim[s] 1 [to 5], in the diagnosis of one of central nervous system (CNS) stress, Alzheimer's disease and disruption of the blood-brain-barrier in a mammal.